Annual results
Annual Results 2012 - Jan 23, 2013
| 2012 (USD m) | 2011 (USD m) | % change (USD) | |
|---|---|---|---|
| Net sales | 56,673 | 58,566 | -3 |
| Operating income1 | 11,511 | 10,998 | 5 |
| Net income | 9,618 | 9,245 | 4 |
| EPS (USD) | USD 3.93 | USD 3.83 | 3 |
| Core2 | |||
| Operating income | 15,160 | 15,909 | -5 |
| Net income | 12,811 | 13,490 | -5 |
| EPS (USD) | USD 5.25 | USD 5.57 | -6 |
- Q4 2012 operating income growth reflects the impact of higher exceptional charges in the 2011 period of USD 1.0 billion, principally due to USD 0.9 billion as a result of exceptional charges relating to Tekturna/Rasilez.
- Core results, constant currencies, and free cash flow are non-IFRS measures. An explanation of these non-IFRS measures and reconciliation tables can be found beginning on page 45 of the Condensed Financial Report.
Media release
| English | German | French |
Interim financial report
(0.4 MB)
Presentation
(1.0 MB)
The information in the presentations on these pages was factually accurate on the date of publication. These presentations remain on the Novartis website for historical purposes only. Novartis assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.
